The Supreme Court’s review of the health care reform law threatens to undermine some of the foundations of pharma planning for the next several decades: a larger insured population with drug coverage, low out-of-pocket costs for drug patients, and substantial IP hurdles for biosimilar challengers. But at the same that the Court is making the Affordable Care Act provisions of the strategic picture more blurry, the court may be clarifying pharma’s continued dominance in the key new field of personalized medicine.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?